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Executive Summary
Pharmacist Recovery Networks (PRNs) are state organizations, typically associated with
a licensing Board of Pharmacy to aid in recovery and monitoring of pharmacists with substance
use disorders with the intention of providing an avenue for pharmacy professionals with
infractions to return to practice. However, there is significant variation in the structure, funding,
and leadership of these organizations leading to high variability in how they serve that purpose
and their efficacy in doing so in a rehabilitative fashion.
The purpose of this project was to assess, in twenty-five strategically chosen US states,
PRN structure, function, and perceptions of Directors regarding allowance of medicationassisted-treatment (MAT). This was done through structured interviews with PRN Directors as
well as publicly available data collection. Results revealed significant variation in the structure
and function of each PRN, including credentials of leadership, funding, and focus on pharmacists
vs. other professionals. Interviews with Directors also revealed several stigmatizing attitudes
toward allowance of MAT as well as existing bias against professionals in recovery from
substance use disorders as somehow “exceptional” in success with abstinence-based treatment.
These findings led to the recommendation that additional research as well as national oversight
of PRN policy is needed to streamline and enhance efficiency of substance use disorder care for
pharmacists.
Introduction
Substance use disorders (SUDs) are a collection of medical conditions which have
reached epidemic levels in the United States. An estimated 40.3 million people over the age of
12 have a substance use disorder, including opioid use disorder, alcohol use disorder, stimulant
use disorder, and cannabis use disorder, among other illicit substances8. These substances either
have no defined medical purpose or have a medical purpose but are misused either by taking
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them outside of medical supervision or in a way other than they are prescribed.
Substance use disorders (often colloquially termed “addiction” outside of the modern
medical community) are complex to identify, especially as recent de-stigmatization efforts to
define them as medical diagnoses, identify comprehensive treatment regimens, and identify
precipitating factors, have come into practice. Where we perhaps once thought in a biased
manner that there was one “type” of person who developed a substance use disorder related to
some moral failing or poor choices, we know now that the science of addiction and alterations in
brain chemistry related to substance dependence are universal in susceptibility. However, there
are several, general, predicting factors for those most likely to develop a substance use disorder
related to history of abuse, high levels of emotional stress or trauma, co-occurring mental health
disorders, and exposure or access to illicit substances9.
Professionals, or those who have achieved a high level of education or training in a
specific field such as medicine, pharmacy, nursing, accounting, etc. face the same exposure and
likelihood of developing substance use disorders, however, are often able to conceal or avoid
social consequences of their disease due to high intelligence and/or socioeconomic status6.
Professionals with substance use disorder or those who have a substance-related infraction
(diversion in the workplace, a DUI, etc.) warranting legal or professional discipline are enrolled
in monitoring programs associated with their professional licensing board with the goal of
attaining re-licensure and the ability to return to professional practice10. These programs are
often referred to as professional health programs (PHPs). However, treatment options and
requirements of those programs are highly variable. PHPs may be “umbrella” organizations,
meaning they represent monitoring and treatment efforts for a variety of professional state
licensing boards, or they may be standalone organizations like pharmacist recovery networks
(PRNs), physician health programs (PHPs), etc.
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Pharmacists are no different in their risk for development of substance use disorder,
however, existing literature regarding management of pharmacist recovery networks (PRNs) is
very limited, and there exists no regulatory agency or board with specified standards for the
running of these programs. The intent of this project was to assess inter-state variability in PRN
practices and policy among twenty-five strategically chosen US states to contribute to the
literature base, including controversial topics such as the use of medication for opioid use
disorder as a treatment strategy in pharmacists.
Literature Review
General Population Substance Use Disorder Risk, Diagnosis, and Management
In recent literature, genetic epidemiological studies have made progress in clarifying how
genetic and environmental factors jointly influence substance use and misuse; there are defined
genetic variants that exist in the general population predisposing one to development of
substance use disorders related to both licit (caffeine and alcohol, for example) and illicit
substances (like cocaine and heroin)11. Epigenetic modifications are the activation of those genes
in response to environmental stressors or “risk or adversity factors:” high levels of emotional
stress, adverse childhood experiences, poverty, discrimination, witnessing violence,
access/exposure to licit or illicit substances, etc.13. So, an individual with a genetic predisposal to
substance use disorder combined with life events that are risk or adversity factors are more likely
to develop a substance use disorder compared to an individual without those two components.
These are also countered in the literature by what are known “protective” factors against
substance use disorder: high quality education, secure housing, higher socioeconomic status,
social attachments and healthy parenting13.
The genetic factors mentioned above are lying dormant in the genetic makeup of a person
and can be thought of as an “on-off” switch, whereas the risk and protective factors exist almost
5

as a “dial.” Throughout life, one is exposed to a variety of risk and protective factors either
raising or lowering their risk for development of substance use disorder development in
combination with their genetic predisposition. It is known that those who attain professional
degrees are more likely to benefit from protective factors earlier in life: positive parental role
models who are likely to have advanced degrees, higher household income, etc14, which in turn
tends to contribute to protective factors within their own households as adults. However, in
healthcare professionals specific unique risk factors exist related to substance access, high stress
in the workplace, and the skewed belief of “immunity” to addiction because of an understanding
of pharmacologic action of substances of use15.
In 2013, the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V,
A standard clinician reference detailing criteria for diagnosis of mental health and substance use
disorders also used in medical coding and billing) was released which included several distinct
changes in the way substance use disorders are assessed and categorized. In this update,
substance use disorder is a clinical, medically defined diagnosis based on problematic patterns of
behavior, in a 12-month period1 (criteria for diagnosis are shown in Table 7, Appendix 1). 2020
marked the first year that the Substance Abuse and Mental Health Services Administration
(SAMHSA) used the DSM-V criteria in assessing prevalence of substance use disorders in their
National Survey on Drug Use and Health (NSDUH)8.
Changes in the definition of SUD and its application are important because they highlight
a shift in the general addiction medicine community from considering tolerance to a substance
alone to be criteria for diagnosis, highlighting the essential behavioral component and continued
use of the substance despite adverse consequences to the individual in the definition of SUD.
This change also emphasizes the spectrum of severity along which SUDs fall, aligning more with
paradigms around mental health disorders and other medical conditions. This opens the field not
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only to embrace harm reduction strategies (clean needle programs, distribution of opioid
overdose reversal agents, and providing resource for safe substance use) when patients are either
unable to or choose not to remain fully abstinent from their substance of use, but also allowing
use of pharmacotherapy options to treat the chemical imbalance in the brain caused by substance
use disorder by replacing that substance to prevent withdrawal or curb cravings that are
historically controversial16.
Current treatment guidelines for SUD include a range of psychological and social
interventions, but arguably the most clinical benefit regarding maintenance of abstinence and
reduction in mortality is seen in patients who are treated with Medication Assisted Treatment
(MAT), both for opioid use disorder and alcohol use disorder11. MAT includes three
pharmacologic products: Buprenorphine, methadone, and naltrexone. Each of these medications
are described in detail in Appendix 2. Briefly, full antagonists of opioids (naltrexone) prevent
any opioid from binding to the receptors responsible for development of dependence, preventing
activation of those receptors for euphoria, sedation, and pain. Naltrexone also works to modulate
the reward pathway in the brain responsible for alcohol use disorder. Partial or full agonists
(buprenorphine or methadone) work to activate opioid receptors at a lower intensity than those
used for misuse, preventing withdrawal and euphoria.
In opioid use disorder, the inefficacy of abstinence-based treatment following
detoxification (elimination of the substance of use and management of ensuing withdrawal
symptoms, typically in a medically supervised setting) is well documented, with patients
receiving MAT having improved treatment retention, decreased return to use of illicit opioids,
and positive trends in a variety of secondary outcomes, including mortality, drug-related HIV
risk behaviors, and criminal activity17. In a systematic review of functional outcomes (cognition,
memory, mood, etc.) on patients receiving MAT for OUD, those patients with OUD who
7

received MAT were found to have significantly improved functional outcomes compared to
those who were treated with cognitive therapy/abstinence-based therapy alone. However,
compared to the healthy population (without OUD), functional outcomes were generally worse
for opioid agonist therapy in categories of aggression, working memory, and cognitive speed18.
There exists a lack of data investigating specific cognitive functioning in occupational tasks
including in specific professional fields.
Professional “Exceptionalism”
Contradictory to the known epigenetic basis of substance use disorders is the concept of
physician or professional exceptionalism: i.e., because of their inherent intelligence or skill that
has allowed them to achieve high educational status and work in an advanced profession, they
should either be immune to development of substance use disorder or able to overcome
dependence on substances through an innate desire to overcome their disease4. Often, this
exceptionalism is a driving factor for promotion of abstinence-based treatment paradigms
regarding Medication Assisted Treatment4.
Aside from perceived personal distinctions, the motivations for recovery that
professionals experience are regarded in the literature as inherently unique and higher than the
average person in recovery4,20. Having dedicated so much of their time, money, and having
personal identity in their field and desire to return to their position drives engagement in
Physician Health Programs or monitoring programs which are analogous to pharmacy recovery
networks. This also supports the theme of “otherness” of the professional community with
substance use disorders; if professionals are inherently different than the rest of the population
seeking treatment, they must then only be able to be effectively managed and monitored by the
intensive treatment strategy that most professional monitoring programs require.
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The themes of exceptionalism and natural predisposition to fare better in treatment is
supported with a limited literature base skewed to favor the success of abstinence based PHPs4.
In the interest of guarding professional reputations and protecting patient privacy in the
community, many physicians and professionals engage in SUD care separately from the general
public. There is a documented shortfall in studies of chemical dependency among healthcare
professionals in relatively short follow-ups compared to the general population, limitations in
statistical methods or analyses, and variable intensity of monitoring19. This selective presentation
of data of successful abstinence has made it more challenging for studies to be approved
regarding MAT in these populations with questions of ethical Institutional Review Board (IRB)
approval in studying buprenorphine compared to “successful” results10.
Additionally, there is a known issue of selection bias in the seemingly positive literature:
Many professionals are coerced into using these programs and others do not seek treatment due
to fear of losing their license, the rigidity of abstinence-only programming, long duration of
monitoring, or fear of criminal repercussions4. The existing belief is that, with no alternatives,
many professionals simply leave their profession without getting treatment, so the treatment
sample is skewed in favor of those who would likely perform well anyway. Additionally, no oneto-one comparator studies exist of prognosis for professionals in treatment programs receiving
abstinence-based care vs. medication assisted treatment4.
Physician Health Programs (PHPs)
Much of the literature for the basis of PRN functionality and structure comes from
physician health programs (PHPs) which have been formally operational in the United States
since the 1970s4. Many of these programs began as voluntary service organizations in which
physicians in recovery would serve as mentors or sponsors (often as part of a 12-step program)
for those currently pursuing recovery. Many of these programs functioned initially as “diversion”
9

or “safe-haven” programs to help physicians with substance related offenses avoid legal or
punitive license repercussions related to an offense5. Beginning in December 1990, the
Federation of State Physician Health Programs (FSPHP) was formed for general oversight and
recommendation setting for PHPs; the organization hosts and sponsors national meetings,
membership, and guidelines for best practices of PHPs.
General recommendations for PHP best practices include: An initial evaluation
(commonly at the expense of the professional/physician in question) at a rehabilitative or
treatment facility (up to 96 hours in duration), follow-up and assessment by
psychiatry/counseling services specializing in addiction medicine, and a minimum 5-year
“contract” to undergo monitoring by the PHP including monitoring and control of all
substances/medications the physician takes, urine drug screens, and regular contact with a case
worker6. This contract will commonly outline a unique set of requirements depending on the
professional’s underlying condition(s) and severity of infraction and details exactly what the
professional must do to regain licensure and exit monitoring requirements at the end of the
contract period. This includes compliance with psychotherapy or counseling, attending group
meetings, adherence to prescribed medications, and monitoring in the workplace (if applicable).
Many of these programs are designed to be abstinence only, meaning no medications to assist
with the underlying disease process of the substance use disorder are permitted21.
Pharmacist Recovery Network Literature
Despite similar risk factors for pharmacists in developing substance use disorder
compared to physicians, there is limited assessment or publicly available information regarding
each state’s Pharmacist Recovery Network. One “organization”, the United States of America
Pharmacists Recovery Network (USAPRN) is a public, non-affiliated, website run by a single
pharmacist from Ohio, Charlie Broussard. This website provides recent contact information for
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each state’s PRN, links to recent individual poster presentations and student publications and
contacts for pharmacists and students23. This website is clearly not analogous to the previously
mentioned FSPHP, which provides oversight, and guidelines for best practices for physician
health programs.
A literature search of “pharmacist recovery networks,” “PRN,” “pharmacist substance
abuse,” and “pharmacist impairment” yielded only one peer-reviewed article assessing PRN
structure and function in 201722. The authors of this study note that it had been 25 years since the
last publication of a report of pharmacist substance use programs22,24. The authors note history of
PRNs beginning in the 1980s with highly variable structure, funding, and extent of services
offered. There is no oversight body in pharmacist recovery networks (like the FSPHP for
physician recovery programs) to provide general oversight or recommendations that are
pharmacist specific. The authors identified rapidly changing program structure (without updates
on public program websites) in response to changing politics and leadership at the state, board of
pharmacy, and programmatic levels22. They also identified trends in some programs being
standalone and others being umbrella organizations that included a variety of professions.
Interestingly, all programs in their study provided monitoring services and support and advocacy
in returning to practice, but very few offer in-house recovery services22. Since 1990, there has
been a pivot from state-run models in which boards of pharmacy or state organizations perform
their own monitoring to an outsourced health care groups or departments of professional
regulation with board-reporting22.
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Problem Definition and Hypothesis
Problem Statement
Among several strategically selected states across the United States, what are differences
in the programmatic structure of professional pharmacy recovery networks, including
perceptions of Medication Assisted Treatment (MAT), including Medications for Opioid Use
Disorder (MOUD), Medications for Alcohol Use Disorder, etc. In a regression analysis of those
states and their demographic and policy characteristics regarding substance use, what trends can
be identified regarding MAT allowance and recovery models for pharmacists?
Hypothesis
After conducting structured interviews with a variety of diverse states’ pharmacist recovery
network coordinators, it is hypothesized that there will be a lack of consensus uncovered regarding
policies on medication assisted treatment and requirements for re-licensure for pharmacists with
substance use disorder enrolled with pharmacist recovery network monitoring and/or treatment. It
is hypothesized that those states with more progressive drug policy and greater access to
medication assisted treatment along with more positive perceptions of medication assisted
treatment will have progressive policies regarding allowance of pharmacotherapeutic treatment for
substance use disorder for working professionals.
Research Design
Data Collection
Twenty-five US States were chosen for assessment based on: their proximity to Kentucky
(where the research is being conducted); opioid overdose death rates (highest and lowest in the
US); those with harsher and more lenient punishment for illicit substance possession or use; and
those with the largest state populations (Table 1).
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Table 1: US States Chosen for Assessment
Florida
California
Texas
New York
Colorado
Washington
Oregon
Louisiana
South Dakota
Hawaii
Iowa
Mississippi
Minnesota

West Virginia
Maryland
New Hampshire
Ohio
Massachusetts
Connecticut
Rhode Island
Kentucky
Maine
Tennessee
Indiana
Missouri
North Carolina
Color Code:
Red = Top 10 states for opioid overdose in the US
Blue = KY Bordering States
Black = States with largest populations
Green = States with more lax drug laws/decriminalization
Purple = States with harsher drug laws
Yellow = Bottom 4 states for opioid overdose

Methods
Contacts for each state’s PRN were found either on the PRN website USAPRN.org
(managed by Charlie Broussard), or through contact with the state’s Board of Pharmacy.
Interviews were conducted in a 30 - 60 minute session via Zoom. Contact emails and catalogs of
outreach attempts to each PRN are included in Appendices 4 and 5 respectively.
After a PRN director’s initial agreement to be interviewed, they received a copy of the
interview questions as well as the results of the University of Kentucky’s Institutional Review
Board (IRB) determination that the project did not qualify as human subject research, and
therefore did not require an IRB protocol. Interviews were recorded for transcribing purposes,
only viewed by this author, and then deleted after transcription.
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Interview questions were either “Informational” or “Programmatic.” Informational
questions included those that are more logistic in nature (e.g., definitions, numbers of individuals
in recovery, percentage of pharmacists achieving re-licensure, etc.), and programmatic questions
included those that require more description/discussion for the reasoning behind them or their
structure (e.g., funding structure, requirements for completion of the program, reasoning for
allowing MAT or not). Selected interview questions are included in Appendix 3.
It was requested at the beginning of each interview that the “Informational Questions”
(Appendix 3) be answered either through provision of their most recent operations report
containing statistics and data on their program or be answered off-line in the interest of time. All
interviewees agreed to submit that question independently at the time of the initial interview.
Regression Analysis
Publicly available information for each state was collected to include in a logistic
regression analysis and identify relationships between state characteristics and PRN
model/allowance of MAT. A full list of independent and dependent variables assessed are
included in Table 2 below.
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Table 2: Independent and Dependent Variables for Regression Analysis
Independent/Explanatory Variables
Dependent
Variable
Population1
Medication
Number of population with grad/professional degrees1
Assisted
2
Treatment (MAT)
Majority political affiliation of state government
allowance in
Percentage of the general population with opioid use disorder3
3
professionals
Percentage of the general population with alcohol use disorder
Percentage of the general population with general substance use
disorder3
# of Opioid Treatment Programs4
# of individuals enrolled in substance use disorder treatment3
Percentage of people enrolled in alcohol use disorder treatment3
Percentage of people enrolled in drug use treatment3
# of patients receiving opioid agonist therapy3
# of X waivered providers5
This information was retrieved from the following publicly available data sources:
1. US Census Data: https://data.census.gov/cedsci/
2. Majority political parties: https://ballotpedia.org
3. SAMHSA 2020 Behavioral Health Barometers (Volume 6):
https://www.samhsa.gov/data/report/behavioral-health-barometer-united-states-volume-6
4. SAMHSA OTP directory: https://dpt2.samhsa.gov/treatment/directory.aspx
5. SAMHSA X-waivered provider directory: https://www.samhsa.gov/medication-assistedtreatment/find-treatment/treatment-practitioner-locator?field_bup_state_value=34
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Sample Results
Outreach attempts to PRN directors occurred from 10/30/2021 - 1/16/2022 (the log of attempts
and resulting outcomes are listed in Appendix 5). Eleven state PRN associations responded: Ten
agreeing to be interviewed with follow-up and one state reported that they did not currently have
a PRN. Two states submitted written responses to the interview questions and elected not to
undergo a live interview.
All participants were asked to submit the Informational Questions (Appendix 3) offline as
well as any statistics or annual reports they had regarding program success or participant
treatment. Four states failed to submit requested follow-up documentation addressed with the
Informational Questions: New Hampshire, Mississippi, Kentucky, and Oregon.
Data Analysis
The small number of observations did not permit robust regression analysis of the data as
originally intended. However, the data collected does suggest a number of patterns which may be
helpful should this work be continued with broader outreach. An index of liberality policy was
created where 0 indicated no Medication Assisted Treatment (MAT) was permitted for clients of
the PRN, 1 indicated only naltrexone (opioid antagonist) therapy was allowed as MAT, and 2
indicating any MAT was permitted, including opioid the agonists buprenorphine or methadone,
which are considered “riskier” in terms of diversion and abuse potential due to acting as an
opioid at the opioid receptor in the brain.
Spearman’s correlation coefficients for non-normal data were used to examine the
relationship between the independent/explanatory variables (see Table 2) and the dependent
variable of MAT use in professionals. Values less than 0.3 were considered low positive
correlations and those greater than 0.6 were considered high positive correlations, indicating
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increasing likelihood of allowing MAT in professionals. Negative values less than-0.3 were
considered low negative correlations and those less than -0.6 were considered high negative
correlations, indicating decreasing likelihood of MAT use26. All correlation coefficients are
shown in Table 3, only those with high positive or high negative correlation are discussed.
Table 3: Correlation Coefficients of Explanatory Variables and MAT Use in PRNs
Drop-out rate of PRN enrolled professionals
Proportion of PRN clientele: Nurses
Proportion of PRN clientele: Physicians
Opioid agonist therapy (Methadone and/or Buprenorphine) allowed?
Return to use rate of enrolled professionals
State median household income
Naltrexone allowed (alcohol use disorder and/or opioid use disorder)?
State alcohol use prevalence (% Heavy Drinking by Education StatusCollege Grad)
Proportion of PRN services: Stimulant Use Disorder
Proportion of PRN services: Polysubstance Use Disorder
State substance use disorder prevalence
State heroin use prevalence
# of staff employed by PRN
PRN contract model: Third party (Y/N)
State marijuana use prevalence
State alcohol use disorder prevalence
Majority political affiliation of state government (R=0, D=1)
PRN funding model: Donations (Y/N)
Proportion of PRN clientele: Pharmacy Students/Interns
Proportion of PRN services: Alcohol Use Disorder
State # of Opioid Treatment Programs
PRN treatment model: Psychotherapy required (Y/N)
State population # enrolled in substance use disorder treatment (2019)
PRN treatment model: Group meetings required (Y/N)
State prescription pain reliever misuse rate
Proportion of PRN clientele: Pharmacists
State population # defined as rural
PRN treatment model: Restricted access to controlled medications (opioids
for pain, medications for anxiety)

94.6%
90.9%
89.6%
80.0%
79.1%
71.0%
67.8%
65.6%
63.2%
54.7%
52.5%
51.4%
49.4%
49.2%
44.7%
43.8%
43.1%
43.1%
39.0%
32.3%
30.9%
30.2%
30.1%
-30.2%
-30.4%
-37.0%
-40.5%
-43.4%
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Table 3: Correlation Coefficients of Explanatory Variables and MAT Use in PRNs

All Board/Staff of PRN Pharmacists? (Y/N)
Successful recovery rate of PRN
PRN contract model: Board-run/Sponsored (Y/N)
State population # enrolled in polysubstance treatment (Drug + Alcohol)
Relicensure rate of PRN participants
Proprotion of PRN services: Cannabis Use Disorder
Proportion of PRN clientele: Pharmacy Technicians
State Tobacco Use prevalence

-45.9%
-48.0%
-49.2%
-51.7%
-57.3%
-61.2%
-64.3%
-64.6%

Explanatory variables strongly associated with allowance of MAT included those PRNs
that function as umbrella organizations, including other professions such as nursing and
physicians. These states were commonly those functioning through an outsourced or external
agency dedicated to addiction management. PRNs that covered a wider range of substance use
disorders (e.g., stimulants, alcohol, etc.) were also more likely to allow MAT use in treatment.
Interestingly, there were strong positive correlations between drop-out and return-to-use rates
and allowance of MAT. Data limitations (e.g., not all states reported drop-out and return-to-use
statistics, and statistics that were reported covered different populations and varying time
periods) constrain the interpretation of this finding.
Factors negatively associated with allowance of MAT included cannabis use disorder
treatment by the PRN, inclusion of pharmacy technicians in PRN monitoring, and higher levels
of tobacco use in the general population. It is unclear what the association of cannabis use
disorder treatment and allowance of MAT could be; perhaps those state PRNs that provide
treatment and monitoring for cannabis use disorder consider cannabis a more concerning drug,
which might translate to stricter overall drug policy and therefore a decreased likelihood to allow
controversial MAT use in professionals. It should be noted that only one state reported
participants in treatment for cannabis, so this finding is unreliable.
18

The negative relationship between a higher proportion of pharmacy technicians included
in the PRN and MAT allowance in the PRN conflicts with aforementioned rationale that perhaps
a broader scope of PRN services enhances the likelihood of MAT use as a treatment strategy.
This is an interesting distinction because pharmacy technicians are monitored by the Board of
Pharmacy, but are not in a high-salary or high-training professional role compared to
pharmacists, and therefore are unlikely to fall under the “professional elitism” umbrella.
The tobacco use finding is interesting, indicating that states with higher proportions of
their population using tobacco are less likely to have a PRN that allows MAT. While it is
impossible to draw any true causality, it is possible that those states with higher tobacco use
could be associated with more conservative policy and thus are less likely to allow MAT.
Pharmacist Recovery Network Trends
Table 4 below includes structural trends among state PRNs interviewed. The
organizations interviewed reported incorporation dates from 1987 to 2016, but all organizations
reported multiple programmatic structural changes since the date of first incorporation, so the
official start “dates” can be unclear depending on the iteration of the PRN in question. Most
organizations are “umbrella” organizations meaning they cover pharmacy and at least one other
profession, though this can vary widely from including pharmacists and other health professions
(such as nursing, dentistry, and physicians) or covering non-healthcare professionals like
accountants, pilots, etc. Interestingly, no PRN interviewed functions as strictly physicians and
pharmacists service model. Pharmacy plus nursing was a more common combination as many
states have independent physician-only monitoring or recovery programs.
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Most organizations feature a Board of Directors (BOD; distinct from the licensing board,
although some states have board-appointed members on their PRN committee). The staff/BOD
typically features a medical doctor as the “medical director” but this person commonly functions
in a consulting capacity for medical decision-making and is not in direct oversight of participants
or involved in intake. Organizations that are pharmacist-centered or direct affiliations with the
Board of Pharmacy are more likely to have pharmacist-led monitoring and supervision. Thirdparty contracted organizations (outsourced, pre-existing, addiction management or substance use
disorder organizations that professional Boards contract with to provide monitoring services)
were more likely to have non-professionals in the role of Director; these individuals commonly
had a history in addiction counseling, but in one case (Iowa) it was noted that this was not
technically a requirement of their job description.
The primary similarity between every organization was they all incorporated some
component of monitoring of professionals. In many cases, participants were able to self-report to
the PRN, meaning the licensing board did not necessarily have to be aware of the individuals’
substance use disorder for them to seek treatment. However, all organizations did note that if a
participant was noncompliant or exhibited “relapse” or return to use (either self-reported or on
biological assay like a urine drug screen), the organization would be obligated to report that to
the licensing board. Only one organization, Colorado, offered in-house biopsychosocial
assessment on intake for participants to identify the extent of the use disorder and treatment
required. All other organizations may offer in-house counseling or support services, but mostly
existed to coordinate and ensure participants were in treatment without engaging with or offering
that treatment themselves.
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Table 4: PRN Structure Trends Among Interviewed Organizations
Client fee Burden
Service Model
Director
Monitoring for In-house
Length of
and Included
continued
Recovery monitoring
Credentials
Professions
substance use services
requirement
included?
Board affiliated
MD
Y
N
5 Years
Urine Drug Screen
New
Hampshire umbrella
(UDS), initial
organization - 13
assessment, counseling,
professional
medical care
licensing boards
Colorado
Third party
RN,
Y
Y
5 Years
External
Umbrella Org
LCSW
counseling/medical care
Mississippi Individual
RPh
Y
Y
5 Years
Client fee, UDS,
volunteer
external
organization
counseling/medical care
(Pharmacist
Centered)
Indiana
LCSW
Y
Y
3-5 Years
Third party
Initial assessment, UDS,
umbrella org –
external
Pharmacy and
counseling/medical care
nursing
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Table 4:
PRN
Structure
Trends
Kentucky

RPh
Y
N
5 Years
Individual
Initial assessment, UDS,
organization –
external
Board contracted
counseling/medical care
(Pharmacist
Centered)
Oregon
RPh
Y
N
5 Years
Volunteer
Client fee, UDS,
peripheral support
external
(Pharmacist
counseling/medical care
Centered)
Maine
Third party
LCSW
Y
N
5 Years
UDS, external
umbrella org
counseling/medical care
Hawaii
Third party
MD
Y
N
5 Years
UDS, external
umbrella org
counseling/medical care
Ohio
RPh
Y
N
5 Years
Individual
Client fee, UDS,
organization –
external
Board contracted
counseling/medical care
(Pharmacist
Centered)
Iowa
LCSW
Y
N
5 Years
Individual
UDS, external
organization –
counseling/medical care
Board contracted
(Pharmacist
Centered)
Missouri
N/A
N/A
N/A
N/A
N/A
N/A
Table definitions:
Table definitions:
■ Pharmacist Centered – Exclusive pharmacist organization serving no other professions; may or may not
include technicians and interns
■ Third-Party Umbrella Organization – External for-profit organization dedicated to addiction recovery
contracted by licensing board(s) to provide monitoring and SUD treatment services. May or may not provide
addiction recovery services to the general public as well
■ Board-Affiliated Umbrella Organization – An organization that receives direction and oversight from several
licensing Boards, but is not incorporated as a for-profit addiction recovery service
■ Individual Organization: Board Contracted – A (typically non-profit) pharmacist-centered organization with
its own funding streams and leadership, but which reports directly to the Board of Pharmacy
■ Volunteer Peripheral Support – An organization not responsible for monitoring or affiliated with the Board
of Pharmacy, but which provides additional support services for pharmacists in recovery beyond what is
available under current PRN structure
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Characteristics of PRN participants are included in Tables 5 and 6 below. Data tracking
among organizations was highly variable, with some reporting lifetime statistics and others only
reporting data from their most recent annual report. Most organizations did not keep strong
records of participants currently in treatment and those who had achieved or failed recovery.
Only Maine and Colorado produced an annual report, other organizations alluded that such a
report existed but did not provide data, and most organizations reported they did not track
participants after monitoring because the participants were not legally obligated to connect with
the PRN after their contract period had finished. A potential concern identified by some
Directors in collecting/providing such data was the concern for maintaining patient privacy and
anonymity; one director reported “When you’re talking about such a small n, reporting the
numbers of participants with certain use disorders who are enrolled it becomes very difficult to
maintain patient privacy, especially when you’re talking about professionals who are hopefully
working in the community.”
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Missouri
New
Hampshire
Ohio
Colorado
Mississippi
Indiana
Kentucky
Iowa
Oregon
Maine
Hawaii

Table 5: Proportion of Clients Served by Profession
Pharmacy
Pharmacy
Physicians Pharmacists
Students/Interns Technicians
-

85%
62%
-

7.5%
34%
-

-

48%
-

-

0%
-

2%
-

82%
-

6%

10% 0%

33%
59%

-

Nurses

Other

-

-

7.50% 4.00% 50% 6%
-

-

0%

0%

0%

6%
-

50%
29%

7%
12%

Table 6: Proportion of Clients Served by SUD Type and PRN Return to Use Rate
Alcohol
Use
Disorder

Missouri
New Hampshire
Ohio

-

Colorado
Mississippi
Indiana
Kentucky
Iowa
Oregon

-

Maine
Hawaii

-

Opioid
Use
Disorder

Stimulant

Cannabis

Other Polysubstance

-

-

-

-

-

30%

10%

10%

0%

30%

20%

5%

17%

50%

17%

0%

8%

0%

11%

75%

-

-

Return to
use Rate

25%

75%

-

0%
-

17%

88%

-

-

0%
-

0%

0%

-

-

0%
-

8%

0

-

-

0%
-

0%

0

-

-

0%

6%

0%

-

-

14%
6%

15%
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While the monitoring component was similar regardless of program structure, the
treatment strategies varied significantly in requirements of psychosocial, pharmacotherapeutic,
and monitoring requirements. Five programs required some sort of group meeting requirement,
commonly 12-step or Caduceus based. Only one program formally required psychotherapy, but it
was noted in all interviews that almost all participants are required to undergo some form of
counseling or psychotherapy. For the 7 programs that required an initial assessment, that
assessment and the recommendation of the treatment team drove the terms of the monitoring
requirement. For example, if the initial external assessment deemed a client must have 6 months
of psychotherapy, 12-step meetings, and inpatient detoxification, those would then be the
requirements conferred by the PRN contract to be eligible for relicensure.
All PRNs reported requiring that any prescribed or over-the-counter (OTC) medication
participants were taking at the time of enrollment, or that were started after enrollment, be
reported with a corresponding prescription or indication from their physician. OTCs taken on an
as-needed basis required contacting the PRN directly before consumption. The first reason for
this documentation requiement by PRN directors was that some medications can cause falsepositives on urine drug screens (UDS)for a variety of controlled substances, so they needed to
have corresponding record of prescription medications should a positive UDS arise to be
contested. Secondly, six PRN directors noted concerns with some medications with sedating
properties as those could promote relapse events. The American Society of Addiction Medicine
(ASAM) Clinical Practice Guidelines report no clinically validated association for patients
taking non-controlled or OTC medications with sedative properties, though they do mention
patients taking controlled prescription medications with sedative, hypnotic, or anxiolytic
properties (such as benzodiazepines) may need a higher level of care. Some of the PRN contracts
and literature cite the Talbott Recovery Campus Medication Guide For a Safe Recovery25 for
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non-controlled medications that participants in recovery should avoid. The Talbott Guide cites
no clinical references in their pamphlet with evidence for why certain non-controlled or over-thecounter medications may be likely to cause relapse, other than they have sedative properties.
Regarding MAT use, all but one (Mississippi) reported use of the opioid antagonist
naltrexone would be permitted for alcohol use disorder or opioid use disorder. Five states
reported they technically have no policy against the use of opioid agonists (buprenorphine and
methadone). However, they also reported that it would be unlikely that a participant would
actually be initiated on opioid agonists except as a last resort, and then not as maintenance
therapy but as a withdrawal management strategy with a plan to taper off and engage in
abstinence-based therapy. For those states who don’t allow MAT and those who do allow it but
do so sparingly, the primary reasons are concerns for drug diversion and abuse potential as well
as the risk of neurocognitive impairment for professionals who return to work.
Director Perceptions
An important component of each interview was understanding each Director’s perception
surrounding MAT use in pharmacists in recovery as well as their general feelings surrounding
pharmacist recovery networks in the overall landscape of professional recovery. Two states,
Colorado and Hawaii, are umbrella organizations that highlighted a new trend in monitoring
programs, where programs expand beyond substance use disorders into the behavioral health
space. This would mean that participants of the program would not necessarily have a substance
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use disorder, but could have a history of workplace aggression or verbal harassment or even
having been newly diagnosed with a mental health disorder and require workplace monitoring.
The criteria for inclusion are broadening, but there is concern that this may open more room for
stigmatization of more people. One PRN Director noted that this brings more concern for
employment, stating “….if you’re involved with the [PRN] you have a substance use disorder
and corporations won’t hire their pharmacists…pharmacy clients often do not complete the
program and leave the profession due to the struggle of finding employment in the field.” This is
especially challenging for states like Colorado that have workplace monitoring duration
requirements before PRN monitoring can cease. If a pharmacist cannot be hired, they cannot be
monitored by the PRN, and thus they reach an impasse in being released from their PRN
contract.
Structure and treatment paradigms were discussed with wide variations in how the PRNs
conduct business. One state reported “meetings are not very structured” and that staff are
“basically pharmacists and pharmacy technicians who have been through the program… or in the
past we have had spouses who wanted to be involved.” Statements regarding licensing board
involvement ranged from “The Board is the boss… we are in charge of collecting information
but they have the ultimate decision” to “The Board has no comment… even on using marijuana
in physician healthcare…They don’t want to be the one to make the decision.” One PRN
Director, also a medical doctor, stated, “Ultimately, we are a monitoring program and to me that
feels so impersonal and also so mechanical [as a physician used to treating patients]…. The
Board should not be making regulatory decisions regarding work limitations, etc…. that should
be us or the professional’s physician.” Discussions around contract and requirement structure
indicated that each contract is unique and while it may have a standard format, each case and
requirements are unique.
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Discussions around treatment paradigms were very interesting, with four states reporting
more progressive or lenient language around MAT and four reporting more stigmatizing
language. One PRN Director of a program that has been operational since the 1980s stated, “…it
was always viewed that there was one way to do everything and so much recovery needed before
you could go back to work… all of those things are essentially artificial… [we] put so many
controls on people to make it more difficult for them to get better… many of these old programs
are run by people who are themselves recovering [from substance use disorders] and it wasn’t
viewed as an illness it was viewed as a moral failing. The remnants of that are pervasive.”
Some states require MAT with opioid antagonists for anesthesiologists with opioid use
disorder before returning to work, citing their access to their substance of choice. Regarding
neurocognitive testing for use of opioid agonists, one PRN director stated “Do we do
neurocognitive testing when we start antidepressants? Those are medications that also effect the
brain…” Another PRN Director highlighted a positive shift in how his organization and state are
viewing suboxone in a “paradigm shift” favoring MAT as a treatment strategy: “…understanding
this more as a medical condition and that you wouldn’t ask someone to discontinue their
psychotropic medications or heart medications before returning to work… people on the Boards
are still a little ‘squirrely’ struggling with stigma and not having addiction backgrounds.”
The stigmatizing language around MAT included statements such as “The Board hates
Suboxone [buprenorphine]… it’s just substituting one drug for another and you need to learn
how to live chemical free.” Interestingly, this quote came from a Director who also stated “The
Board has gotten more lenient as far as timelines [of monitoring], but years ago we had a bunch
of people relapse at 5 years so the board made us increase to 10 years.” Another PRN Director
who also manages non-professional clients and incarcerated individuals with substance use
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disorders stated: “[my other patients who have been on Suboxone (buprenorphine)] told me they
would rather detox off heroin than any of those [other opioid agonists like methadone or
buprenorphine] and taught me about how they abuse them…. In states that allow MAT you have
to be on extensive quarterly neurocognitive testing which is very expensive.” One PRN Director
noted, “I don’t know that there have been enough studies on health professionals and MAT…
Vivitrol [naltrexone, an opioid antagonist] would be preferred.” Finally, a last PRN Director
echoed the employment and MAT concern, stating “We never had anyone on Suboxone who was
allowed to go back to work.”
Discussion
The results of the qualitative portion of this study support the initial hypothesis that there
is a significant lack of centralization regarding pharmacist recovery networks that is allowing
pervasive stigma in some states to harm professional recovery and re-entry to practice. All state
PRNs function primarily as monitoring programs, with those PRNs with greater resources,
through larger contracts covering more state professional licensure Boards, commonly offering
expanded services, though some still charge a fee for enrollment in addition to the cost of all
assessments and treatments required. This cost is one major concern in the current treatment
paradigm; some PRNs take a portion of all licensing fees to fund their operations as a type of
“insurance” policy should any pharmacists require support, but costs of external assessment by a
psychiatric treatment facility and the generally required five years of monitoring with associated
costs of testing are still not covered and can be prohibitive to a pharmacist who cannot find or
retain employment due to their disease.
With no formal oversight board like the Federation of State Physician Health Programs
(FSPHP) advocating for pharmacists in recovery or providing a set of guidelines or
recommendations for how to implement current substance use disorder practice guidelines into
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treatment, PRN functionality is left to the historic standard of practice in each state. This
perspective is commonly biased because the PRN is operated in a volunteer fashion or by
professionals who feel moved to engage in PRN management because of a personal history with
substance use disorder and the desire to share their recovery and promote recovery in others.
While the peer support model has been shown in the 12-step paradigm to be a beneficial
component of treatment, recent developments in addiction science and medical practice show us
that this is not a space exempt from requiring specialist attention in treatment and management.
This requires leadership be adequately trained in addiction medicine with corresponding
credentials to make pharmacotherapy decisions for pharmacists in recovery. This will likely
improve the stigmatizing comments from some PRN Directors interviewed in this study, as those
Directors who had more specialized training and were not relying solely on personal addiction
experience were less likely to display stigmatizing language surrounding the use of MAT.
Future Directions and Policy Recommendation(s)
A major limitation of this study is the lack of participation of the full intended cohort of
PRN Directors, which even at maximum participation, represented only half of the United States.
Because there are pharmacists in every state, it is essential that we understand what services are
being offered and how they are designed so that essential gaps in care can be acknowledged and
managed the best way possible. Further work should focus on continued outreach and assessment
of these organizations with as much data regarding their treatment strategies and success
collected as possible. In all other areas of medicine, we depend on strong, objective evidence and
demonstrated efficacy to guide practice. Substance use disorder treatment is a clinical space that
has not upheld that standard in current practice, perhaps in large part due to stigma and the
pervasive belief of “exceptionalism” in professionals. It is impossible to move forward without
true knowledge on whether the current system is functional.
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When sufficient evidence and knowledge of exactly how PRNs are functioning
throughout the US is gathered, a formalized regulatory board, similar to what exists for
physicians (i.e., the FSPHP), must be created dedicated to guiding pharmacist recovery network
policy. The benefits of such an organization include:

1. Standardization of best practices, ideally led by professionals in addiction medicine with
experience in treating patients with substance use disorders and not only experienced in
their own recovery
2. Clear expectations of data collection and tracking, which would both promote
investment in the success of each client and the organization by Directors and staff and
provide insight into trends and evolving needs of current treatment paradigms
3. A formalized network of contacts for PRN Directors, staff, clients, and Boards of
Pharmacy to connect, gain ideas, and identify commonalities in states with similar
populations and policies
4. Oversight of PRNs not adhering to defined best practices, which would protect those in
recovery against discriminatory behavior that they currently have no buffer from if they
desire to regain their license

While each state’s needs are unique and states cannot be expected to function in an identical
fashion, having standards and oversight by one national organization will ensure that pharmacists
across the US will have access to the same resources, regardless of the opinions or existing
biases of their state PRN Director.
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Addendum—March 25, 2022
A testament to the timeliness of this work, on March 25, 2022 the Indiana Justice
Department found that the Indiana State Board of Nursing violated the Americans with
Disabilities Act (ADA) by prohibiting nurses with Opioid Use Disorder on MAT from
participating in the Indiana State Nursing Assistance Program. The Indiana State Nursing
Assistance Program and the Indiana Pharmacist Recovery Network are both serviced by the
same recovery organization, the Indiana Professionals Recovery Program. The official statement
from Assistant Attorney General Kristen Clarke included, “Recovery and monitoring programs
must allow individuals to use proven medications that support their recovery, including
prescribed medications that treat Opioid Use Disorder [methadone and buprenorphine] ….
Opioid Use Disorder is a difficult disease that impacts people in every occupation. Patients must
not be forced to choose between medically approved treatments and their livelihoods.”
This report is monumental in not only advocating for the safety and efficacy of MOUD,
but also showcases the beginnings of the proposed regulation and oversight recommended in this
manuscript for Pharmacist Recovery Networks. Having a standard, mandated, requirement for
adherence to evidence-based practice regardless of a person’s profession is essential in
minimizing bias and stigma of substance use disorder among professionals. The publicity of this
case will, hopefully, bring to light other state instances where pharmacists and professionals in
recovery have not been treated fairly, and will hopefully incite a new wave in professional SUD
management.
Retrieved from: https://www.justice.gov/opa/pr/justice-department-finds-indiana-state-nursingboard-discriminates-against-people-opioid-use
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Appendix 1: Diagnostic Criteria for Diagnosis of Substance Use Disorder
Table 7: DSM-V Criteria for Diagnosis of Opioid Use Disorder
Mild = 2-3 criteria
Moderate = 4-5 criteria
Severe = 6+ criteria
Substances are often taken in larger amounts or over a longer period of time than intended
There is a persistent desire or unsuccessful efforts to cut down or control substance use
A great deal of time is spent in activities necessary to obtain the substance, use the substance,
or recover from its effects
Craving, or a strong desire to use substance
Recurrent substance use resulting in failure to fulfill major role obligations at work, school, or
home
Continued substance use despite having persistent or recurrent social or interpersonal
problems caused or exacerbated by the effects of opioids
Important social occupational, or recreational activities are given up or reduced because of
substance use
Recurrent substance use in situations in which it is physically hazardous
Continued substance use despite knowledge of having a persistent or recurrent physical or
psychological problem that is likely to have been caused or exacerbated by the substance
*Exhibits tolerance
*Exhibits withdrawal
*Tolerance is defined as a need for markedly increased amounts of opioids to achieve
intoxication or desired effect or a markedly diminished effect with continued use of the same
amount of a substance. Withdrawal refers to a series of symptoms (Dysphoric mood,
nausea/vomiting, muscle aches, sweating, runny nose or watery eyes, diarrhea, fever,
insomnia, etc) following cessation of substance use that has been heavy and prolonged (weeks
or longer) or administration of an opioid antagonist such as Narcan (naloxone)1. Avoidance
of withdrawal, which can be highly dangerous in severe cases and extremely uncomfortable
even in mild cases, is a major factor in continued opioid use.
Tolerance and withdrawal are physiologic phenomena not unique to SUDs, as these can occur
without social or psychological repercussions associated with true SUD. As such, they are not
requirements for SUD diagnosis for patients taking opioids under medical supervision, for
example.
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Appendix 2: Discussion of Medication Assisted Treatment (MAT) Options
Naltrexone is a full antagonist of opioid receptors in the brain, meaning it blocks the
activity of opioids at opioid receptors in the brain, preventing any typical reward an OUD patient
may experience when they use their substance of choice (heroin, oxycodone, etc.). A patient on
naltrexone may take their opioid of choice but won’t derive any of the “high” or typical
pleasurable benefit they normally would achieve. Naltrexone is non-habit forming and will not
precipitate withdrawal if discontinued, however, it does require abstinence from opioids for 7-10
days minimum prior to initiating therapy to avoid precipitated withdrawal caused by naltrexone
“kicking off” the opioid from the target receptors. This is of course a significant challenge for
patients with OUD experiencing cravings as they will go through a natural withdrawal period in
those 7-10 days off opioids. Recently, naltrexone has been found to be highly effect in alcohol
use disorder in regulating the reward pathway those with AUD experience upon alcohol
consumption.
Buprenorphine is a partial agonist at the opioid receptor – rather than blocking the
beneficial effects of opioids in the brain, buprenorphine partially mimics them, binding and
offering withdrawal-prevention without the psychotropic or rewarding psychological effects
from the OUD patient’s substance of choice. Buprenorphine can confer a less-severe risk of
precipitated withdrawal while de-escalating from illicit opioids, as well as a highly reduced risk
of overdose and death secondary to respiratory depression. Regulation of buprenorphine as a
controlled substance can pose several barriers to access, as it is a controlled substance, but it is
accessible on a take-home, outpatient basis. There have been concerns posited regarding
buprenorphine’s potential for abuse and diversion as a street drug as well as concerns of
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continued cognitive impairment similar (though much less severe and debilitating) to use of
chronic full-agonist opioids.
Methadone is a full agonist at the opioid receptor – providing the full effect of the opioid
in the brain of patients with opioid use disorder but doing so much more slowly than short acting
opioids like heroin or oxycodone. This prevents the development of euphoria while still
preventing withdrawal. Methadone, however, is much more tightly regulated because of its abuse
potential, and is only available for the treatment of Opioid Use Disorder under daily observed
dosing through Opioid Treatment Programs (OTPs), making it unrealistic for many patients.
Appendix 3: PRN Interview Questions
Note: Questions discussed in live interview with state PRN affiliates included primarily
programmatic details, and PRN contacts/directors were asked to submit Informational Questions
through providing an annual report or separate responses with statistics/demographic
information.
Informational Questions
1.1 What is the “name” of the pharmacist recovery network (PRN) in your state?
1.2 When was the PRN founded in your state?
1.3 Description of PRN leadership and personnel:
1.3.1 How many individuals does your state’s PRN employ? What are their
credentials?
1.3.2 Does your state’s PRN include volunteers? If so, how many? How are
these individuals identified (e.g., appointed by the Board of Pharmacy?)
and what are their credentials?
1.4 How does your state’s PRN conduct business? (e.g., Monthly meetings? Meetings as
needed?)
2.1 What is the approximate proportion of individuals currently participating in your
state’s PRN with: We also have participants with mental health conditions
a. Alcohol use disorder:
b. Opioid use disorder:
c. Stimulant use disorder:
d. Cannabis use disorder:
e. Other substance use disorder:
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f. Poly-substance use disorder:
2.2 On average, what is the approximate number of individuals seeking services from
your state’s PRN per year: It ranges throughout the year. However currently we have:
g. Pharmacists:
h. Pharmacy students:
i. Pharmacy interns:
j. Pharmacy technicians:
k. Others:
2.3 What is the approximate relapse rate for individuals who complete your state’s PRN
program?
2.4 On average, what is the approximate percentage of individuals who drop out of your
state’s PRN program each year?
2.5 Approximately what percentage of individuals who complete your state’s PRN
program achieve recovery?
2.6 Approximately what percentage of pharmacists who complete your state’s PRN
program achieve re-licensure?
2.7 How does your state’s PRN refer to individuals participating in the program?
(Clients? Other?)
3.1 Does your state’s PRN include recovery from non-substance addictions? (e.g.,
gambling)
3.2 Are there differences in how the program operates for pharmacists facing legal
ramifications as a result of their SUD? If so, please describe.
Programmatic Details
4. Where is your state’s PRN “housed” (e.g., Outsourced with board oversight? Stand-alone
program? Other?)
5. Description of PRN oversight: How involved are regulatory agencies (BOP, etc.) in your
state’s PRN decision-making?
6. How is your state’s PRN funded / Who pays for the services provided by your state’s
PRN? (e.g., State appropriation? Donations? Board of Pharmacy? License-renewal fees?
Other?)
a. What are the licensing fees?
7. Are there other professional recovery networks in your state that work closely with your
state’s PRN? (e.g., Medical? Dental? Veterinarian? Law? Others?)
a. What are the similarities and differences between the pharmacist recovery
network in your state and these other professional recovery networks?
8. Does your state’s PRN include:
b. Student pharmacists / interns?
c. Pharmacy technicians?
9. How are pharmacists referred to the program? (e.g., Self-referred? Auto-referred after an
event or report? Both? Other?)
10. Is the treatment pathway the same regardless of the referral method used?
11. Is there a suggested or required diagnostic process for participants in the program? (e.g.,
Length of assessment? Diagnostic Urine Drug Screen / biomarkers? Other?)
12. Does your state’s PRN differentiate between “substance use” and “substance use
38

disorder”?
13. What are the requirements of your state’s PRN program?
d. Duration?
e. Psychotherapy?
f. Group meetings?
g. Do you have a contract that you incorporate into your recovery program with
patients? Can you share a copy of that contract?
14. What are the requirements for re-licensure in your state?
15. Does your state’s PRN track pharmacists who successfully complete the program? If so,
how?
16. Does your state’s PRN restrict a participant’s access to any non-controlled prescription or
over-the-counter medications? (e.g., anti-epileptics, anxiolytics, pain therapy, antidepressants, anti-psychotics, antihistamines, etc.).
h. What about vitamins? Supplements? Homeopathic remedies?
17. How does your state’s PRN define Medication Assisted Treatment or MAT?
18. Does your state’s PRN use / permit MAT in any phase of the PRN program?
a. Does your state’s PRN allow MAT for some SUDs and not others (e.g.,
naltrexone for Alcohol Use Disorder, but not Suboxone for Opioid Use Disorder)?
b. Describe the rationale for using / not using MAT.
19. If your state’s PRN does allow MAT, which medications are permitted? Are there any
medications that are restricted?
c. Do pharmacists in the program who use MAT have any additional requirements
they have to meet compared to those who do not use MAT?
20. Do the other professional recovery programs in your state allow MAT?
d. Do you have any insight into why they do / do not allow MAT?
Appendix 4: Initial Contact Email and Scheduling Email
Initial Contact Email:
Good morning,
My name is Lindsey Porter, and I am a 4th year Pharmacy Student and Master of Public
Administration Student (PharmD/MPA) at the University of Kentucky College of Pharmacy and
the Martin School of Public Policy and Administration in Lexington, Kentucky.
As part of my curriculum, I am conducting a capstone research project regarding Pharmacist
Recovery Networks (PRNs). One component of my project is to collect information about interstate variability in how these organizations serve pharmacists struggling with substance use
disorders. I am planning to conduct structured interviews with PRN directors/coordinators in 25
different states. If possible, I would like to include <STATE>. The interview would last no more
than 20 minutes, and could be conducted via Zoom or phone, whichever is most convenient for
you.
If you are willing, I would be glad to send you the questions in advance and work with you to
find a time that is mutually beneficial to meet. I would be very grateful for your contribution to
my Capstone project.
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Thank you for your consideration, and I look forward to hearing from you.
Best,
Lindsey Porter
Follow-Up Email (with interest)

Good afternoon <Director>,

Thank you very much for agreeing to chat with me regarding the Pharmacist Recovery Network
organization in Indiana, and I apologize for my delay in following up with you as my advisors
and I confirmed final preparation for my work with each state. I wanted to inquire about your
availability for our ~20-minute interview <DATES>. Anytime those days (including evening
hours if needed) I would be happy to accommodate. I will send an Outlook invitation pending
your availability.
As a few housekeeping items before we meet:
•

I want to be sure that you understand that the University of Kentucky Institutional
Review Board views our conversation as research that does not involve human subjects,
because I am only confirming (or obtaining) publicly available information about
Indiana’s PRN. I am not collecting any personal opinions or personal information.

•

My list of intended interview questions is attached. They are organized based on question
"type:" Informational Questions (1-3.2) and Programmatic Questions (4-20). Some
questions, particularly 1-3.2, may be more easily answered via email and could be
answered and sent before or after the interview, if you prefer.

•

Please let me know at the beginning of or during our interview if you or your
organization would prefer to skip any questions

•

If you are comfortable, I would like to record the session via Zoom solely for
transcription purposes (Only to be viewed by me and deleted when finished transcribing).
However, if you are not comfortable with this I of course understand and will not record.

I look forward to hearing from you and scheduling a time to meet. Please let me know if you
have any additional questions or concerns.
Best,
Lindsey Porter
Follow-up email (no contact)
Good morning <PRN Director>,
I wanted to follow up with you regarding the below message as I fear it may have gotten lost. My
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name is Lindsey Porter and I am a 4th year PharmD/MPA student at the University of Kentucky
College of Pharmacy. I am connecting with Pharmacist Recovery Network
Directors/Coordinators from 25 US states to assess interstate variability in structure, function,
and allowance of medication-assisted-treatment (MAT).
Would you be available for a brief interview to discuss <STATE>'s PRN? Since I last reached
out, we have formalized the list of interview questions, which I have attached to this email to
give you a better idea of the information I'm requesting from each state's PRN. Additionally, the
University of Kentucky Institutional Review Board views our conversation as research that
does not involve human subjects, because I am only confirming (or obtaining) information about
<STATE>'s PRN. I am not collecting any personal opinions or personal information. I am happy
to forward the determination email from the IRB for your records, if desired.
My goal is to complete interviews by the second week of January 2022 to ensure I have adequate
time to analyze all responses and complete my full manuscript. If you are willing to participate in
my project, could you please let me know by 12/10/2021 so we can hopefully find a mutually
beneficial time? Either way, thank you very much for your time and for the work you are doing
to aid pharmacists and professionals in recovery.
I look forward to hearing from you.
Best,
Lindsey
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Appendix 5: Outreach Attempts with PRN Directors
Complete Interviews
Initial
Contact
Date
New Hampshire
10/30/21
Colorado
10/30/21
Mississippi
10/30/21
Indiana
10/30/21
Kentucky
10/30/21
Oregon
10/30/21
Maine
10/30/21
Hawaii
10/30/21
Ohio
10/30/21

Second
Contact
Date
12/1/21
12/1/21
12/1/21
11/24/21
12/1/21
12/1/21
12/1/21
12/1/21

Third
Contact
Date
1/13/22
1/16/22
1/16/22
-

Iowa
Missouri

12/1/21
-

-

10/30/21
10/30/21

Incomplete Interviews
Initial
Contact
Date
Florida
10/30/21

Second
Contact
Date
12/10/21

Third
Contact
Date
12/14/21

Tennessee

10/30/21

12/1/21

1/13/22

Rhode Island

10/30/21

12/1/21

1/13/22

West Virginia

10/30/21

12/1/21

1/13/22

Minnesota

10/30/21

12/1/21 (Jim
Alexander)

1/16/22

California

10/30/21

12/1/21

-

Interview Date
12/15/21
12/16/21
12/16/21
11/30/21
12/8/21
1/17/22
1/24/22
1/28/22
12/3/21 *Elected to submit responses to questions
electronically rather than live interview
12/9/21
Received word 11/2/2021 that there is no active
PRN in Missouri from Jennifer Boehm at Missouri
BOP
Result
Received response 12/13 would need to reach out
to MQA nursing department for assistance; final
outreach attempt was with them but no response
Contact Baeteena Black (attempts 1 and 2) never
responded) – F/u email to TN BOP went
unanswered
Contact Peter Ragosta (attempts 1 and 2) never
responded – F/u email to RI BOP went
unanswered
Contact Mike Brown (attempts 1 and 2) never
responded – f/u email to WV BOP went
unanswered
Received initial response from Monica Feider that
I should contact Jim Alexander on follow up (cc’d
him on email)
Initial email to CA BOP went unanswered, called
CA BOP 12/1/21 and was unable to speak to a live
representative for information
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Initial
Second
contact date contact date

Incomplete
Interviews
Connecticut

10/30/21

12/1/21

Third
contact
date
1/13/22

New York

10/30/21

12/1/21

1/13/22

Washington

10/30/21

12/1/21

1/13/22

Louisiana

11/4/21

12/1/21

1/13/22

Maryland

10/30/21

11/24/21

1/13/22

Massachusetts

10/30/21

12/1/21

1/13/22

Texas

10/30/21

12/1/21

1/16/22

North Carolina

10/30/21

12/1/21

1/16/22

Result
Contact Margie Giuliano (attempts 1 and 2) never
responded – f/u email to CT BOP went
unanswered
Initial contact to NY PAP (attempts 1 and 2) went
unanswered; attempted to call phone number
available online, was unable to connect with live
representative
Initial contact to William Rhodes (attempts 1 and
2) went unanswered; Email to contact WA BOP
went unanswered
Initial contact to T. Morris Rabb (attempts 1 and
2) went unanswered; Email to contact LA BOP
went unanswered
Contact Rob White responded initially he would
be excited to participate, responded to scheduling
email that he needed BOP approval (12/4)
Contact Edmund Taglieri initially responded he
was interested pending board approval with the
questions, but never responded to scheduling
email
Contact Raquel Leal initially responded she was
interested and looking forward to receiving
questions/more information, but never responded
to scheduling email
Contact Joseph Jordan initially responded he was
interested in receiving more information, but never
responded to scheduling email
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Appendix 6: Publicly
Available Data
State prescription

1

1

1

1

1

1

1

653

405

2488

1097

265

861

1025

6210

3877

19496

6686

1621

8994

10538

Polysubstance (drug)

39.60%

20.00%

36.10%

34.90%

47.40%

33.60%

29.50%

Drug use only

45.70%

69.60%

49.00%

34.50%

41.10%

50.10%

61.00%

Alcohol use
# Enrolled in treatment

14.60%

10.40%

14.90%

30.70%

11.50%

16.30%

9.50%

19996

6473

66296

52388

6179

37077

28452

# of Opioid

17

11

102

30

5

23

28

Recreational

# of x waivered
# of patients

0

0

0

1

0

0

0

Drug Overdose

2121

381

5472

1832

682

2666

2373

Alcohol Induced

791

218

1599

1568

389

1027

738

General Substance

7.10%

9.10%

7.70%

11.70%

6.30%

7.90%

7.50%

Alcohol Use

5.10%

7.00%

5.10%

8.50%

4.40%

5.40%

5.00%

Opioid Use Disorder

0.50%

0.80%

1.40%

0.70%

0.60%

1.00%

1.30%

Prescription Pain

3.80%

3.30%

4.50%

4.60%

3.90%

4.60%

4.40%

Heroin Use (General)

0.14%

0.50%

0.53%

0.33%

0.11%

0.39%

0.42%

Marijuana Use

15.20%

20.90%

15.00%

27.50%

11.80%

16.00%

14.60%

Tobacco Use

29.50%

25.60%

32.70%

27.50%

35.60%

32.60%

37.00%

Alcohol Use

0.07%

8.90%

6.40%

8.60%

4.30%

5.80%

6.70%

0

0

0

1

0

0

0

Urban

4627568

850184

9340241

5046618

1406223

5266269

2630526

Rural

1509860

509527

2348859

712118

1569926

1465950

1837147

$

$

$

(% Majority Political)

Med. House Income

$

$

Grad/Prof Degree
Population

Coding Key:
• For all Y/N Questions, 1 =
Y, 0 = N
• For questions of political
affiliation, 1 = Democrat, 0 =
Republican
A dash in a cell "-" indicates
that state did not provide
associated data for that
metric

$

466719

199878

1297490

1577894

255949

653025

460170

6137428

1359711

11689100

5758736

2976149

6732219

4467673

Interview Completed
State

$

0
Missouri

1
New York

1
Ohio

1
Colorado

1
Mississippi

1
Indiana

1
Kentucky

Appendix 6: Publicly Available Data (con't)
State prescription

1

1

1

1

192

907

477

167

1911

7122

5091

1035

Polysubstance (drug)

50.50%

34.00%

32.80%

38.60%

Drug use only

31.70%

48.50%

48.20%

48.20%

Alcohol use

17.80%

17.50%

19.00%

13.20%

# of x waivered
# of patients

# Enrolled in treatment

8838

20268

14550

5217

# of Opioid

8

24

12

5

Recreational

0

1

1

0

Drug Overdose

448

1054

567

250

Alcohol Induced

524

1134

286

131

General Substance

8.50%

10.20%

8.80%

8.40%

Alcohol Use

6.50%

7.70%

5.70%

6.30%

Opioid Use Disorder

0.70%

1.00%

1.20%

0.60%

Prescription Pain

4.30%

5.10%

2.80%

4.00%

Heroin Use (General)

0.11%

0.47%

0.82%

0.18%

Marijuana Use

12.40%

27.70%

24.20%

15.40%

Tobacco Use

29.00%

26.50%

25.70%

21.70%

Alcohol Use

6.30%

8.80%

8.70%

6.60%

0

1

1

1

Urban

1689120

3527713

796931

1141945

Rural

1465950

690024

547281

273927

(% Majority Political)

Med. House Income

$

Grad/Prof Degree
Population
Interview Completed
State

Iowa

$

$

$

299732

569394

166682

164241

3155070

4217737

1344212

1415872

1

1

1

1

Oregon

Maine

Hawaii

Coding Key:
• For all Y/N Questions, 1 = Y, 0 = N
• For questions of political affiliation, 1 =
Democrat, 0 = Republican
A dash in a cell "-" indicates that state did not
provide associated data for that metric
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